BioXcel Therapeutics announced via a regulatory filing plans to raise as much as $69 million via an initial public offering (IPO), as reported NASDAQ.
The terms of the IPO were not divulged.
FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>
To read more NewsPoints articles, click here.
